ITEM VIEW

Kaposi’s sarcoma : good outcome with doxorubicin, bleomycin and vincristine sulphate (ABV) chemotherapy and highly active antiretroviral therapy

dc.contributor.authorHesseling, P. B.en_ZA
dc.contributor.authorKatayi, E.en_ZA
dc.contributor.authorWharin, P.en_ZA
dc.contributor.authorBardin, R.en_ZA
dc.contributor.authorKouya, F.en_ZA
dc.contributor.authorPalmer, D.en_ZA
dc.contributor.authorGlenn, M.en_ZA
dc.contributor.authorKruger, Marianaen_ZA
dc.date.accessioned2018-11-27T07:42:55Z
dc.date.available2018-11-27T07:42:55Z
dc.date.issued2017
dc.identifier.citationHesseling, P. B., et al. 2017. Kaposi’s sarcoma : good outcome with doxorubicin, bleomycin and vincristine sulphate (ABV) chemotherapy and highly active antiretroviral therapy. South African Medical Journal, 107(11):952-953, doi:10.7196/SAMJ.2017.v107i11.12559en_ZA
dc.identifier.issn2078-5135 (online)
dc.identifier.issn0256-9574 (print)
dc.identifier.otherdoi:10.7196/SAMJ.2017.v107i11.12559
dc.identifier.urihttp://hdl.handle.net/10019.1/104733
dc.descriptionCITATION: Hesseling, P. B., et al. 2017. Kaposi’s sarcoma : good outcome with doxorubicin, bleomycin and vincristine sulphate (ABV) chemotherapy and highly active antiretroviral therapy. South African Medical Journal, 107(11):952-953, doi:10.7196/SAMJ.2017.v107i11.12559.en_ZA
dc.descriptionThe original publication is available at http://www.samj.org.zaen_ZA
dc.description.abstractThere is little published information on effective treatment of Kaposi’s sarcoma (KS) in children in low-income countries. We prospectively treated 12 patients with an institutional review board-approved protocol consisting of four monthly courses of doxorubicin (Adriamycin), bleomycin and vincristine sulphate (ABV), with highly active antiretroviral therapy (HAART) plus co-trimoxazole prophylaxis for those who were HIV-positive, with additional vincristine if remission was not achieved after 4 months. Maintenance HAART plus co-trimoxazole was given to all HIV-positive patients. A fine-needle aspirate and CD4+ count were done if possible, and staging was performed according to Mitsuyasu. Eight of ten HIV-positive patients with stage III - IVB disease, and both HIV-negative patients with stage I disease, were in remission after 473 - 1 490 (mean 939) days. One patient died after absconding during treatment, and one died from neutropenia-related pulmonary infection. ABV with or without HAART is an effective treatment option for children with KS.en_ZA
dc.description.urihttp://www.samj.org.za/index.php/samj/article/view/12109
dc.format.extent2 pagesen_ZA
dc.language.isoen_ZAen_ZA
dc.publisherHealth & Medical Publishing Groupen_ZA
dc.subjectHIV-positive children -- Treatmenten_ZA
dc.subjectKaposi's sarcomaen_ZA
dc.subjectAntiretroviral therapyen_ZA
dc.subjectDoxorubicinen_ZA
dc.subjectCancer -- Chemotherapyen_ZA
dc.subjectBleomycinen_ZA
dc.subjectVincristine sulphateen_ZA
dc.titleKaposi’s sarcoma : good outcome with doxorubicin, bleomycin and vincristine sulphate (ABV) chemotherapy and highly active antiretroviral therapyen_ZA
dc.typeArticleen_ZA
dc.description.versionPublisher's versionen_ZA
dc.rights.holderHealth & Medical Publishing Groupen_ZA


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

ITEM VIEW